SVB Leerink analysts recently decreased the Q1 2022 EPS estimate of Medtronic PLC (NYSE: MDT). The announcement was made in a report issued on 24th February by the brokerage. The firm currently expects the medical technology company to post an EPS of $1.36 in Q1 2022. This is down from their previous estimate of $1.39.
The brokerage has also issued a revised “market perform” rating on the stock along with an average target price of $129.00. Along with the Q1 2022 analysis, MDT is also expected to report $1.49 as EPS for Q3 2022 and $1.45 for Q4 2022.
MDT stocks traded at a peak of $117.20 this Friday. The company’s current market capitalization stands at $157.75 billion. It has a positive PE ratio of 45.00 along with a beta of 0.70 at the moment. The PEG ratio stands at 3.65. The current ratio is 2.16 and the quick ratio is 1.79. The debt-to-equity ratio stands at 0.52. The 12-monthly high to low ranges from $120.53 to $72.13. The 50SMA (Simple Moving Average) stands at $116.84 and its 200SMA stands at $110.46.
NYSE: MDT Stock Analysis
The quarterly earnings report for the previous fiscal quarter was released by the company on the 23rd of February. The earnings stood at $1.29 EPS for that quarter as opposed to the general consensus of $1.15. The company’s return on equity stands at 9.71% along with a net margin of 12.69%. Analysts from several brokerages suggest that the company is likely to announce 1.44 as earnings per share for the current fiscal year.
NYSE: MDT has recently been the subject of a lot of reports by equities analysts. Some such as Truist, UBS Group, Cowen, Raymond James, Citigroup Inc., and so on have posted reports on this firm over the last few weeks. All these brokerages have lifted their target price for the company, as per their reports.
The consensus rating of MDT stocks stands at “Buy.” The consensus on the target price is marked at $122.50. Several hedge funds have also altered their shareholdings of this company recently.